Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value
$10.99−0.21 (-1.87%)
Close on Nov 13, 2026Market cap $320.09MP/E –Yield –
Enanta Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Enanta Pharmaceuticals's EV/EBITDA was 38.0× on Jul 31, 2020, against 12.8× a year earlier. Over the last 5 years it ranged from 2.7× to 52.4×, with a median of 14.6×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2020 | Jul 31, 2020 | 38.0× | +15.9 |
| 2019 | Dec 31, 2019 | 22.1× | +10.3 |
| 2018 | Dec 31, 2018 | 11.7× | −21.9 |
| 2017 | Dec 29, 2017 | 33.6× | +14.5 |
| 2016 | Dec 30, 2016 | 19.1× | +15.3 |
| 2015 | Dec 31, 2015 | 3.8× | −40.4 |
| 2014 | Dec 31, 2014 | 44.2× | +2.3 |
| 2013 | Dec 31, 2013 | 41.9× | – |
See a number that looks wrong?